Fate Posts $139M Cash, Mid-2028 Runway; FT819 Lupus Data Shows 100% Renal Response
FATE has more than doubled off its 52-week low of $0.95.
Summary
Fate ended Q3 with $139.1 million in cash and investments and says that plus the $15.0 million CIRM grant funds operations into mid-2028 — a runway extension that removes near-term financing pressure for a company this size. The quarter's net loss was $30.7 million, or $0.25 per share, with operating expenses of $32.2 million, down from $36.5 million a year ago as R&D and G&A cuts take hold. The clinical update is the real story: updated Phase 1 FT819 data presented at ASN Kidney Week showed 100% renal response in the two bendamustine-conditioned lupus nephritis patients with Month 6 follow-up, and no CRS above Grade 2, no ICANS, and no GvHD across 29 autoimmune patients on the fludarabine-free regimen. That supports the design of RECLAIM-LN, now enrolling at 17 sites with roughly 53 patients planned. They also added Jamie Harrell, formerly of Aurinia, to a new commercial role, and expect to dose the first FT839 COMPLETE patients by year-end. Four FT819/FT839 abstracts are slated for ACR Convergence November 6-11, which is the next scheduled data readout.
At the time of this announcement, FATE was trading at $2.07 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $250.4M. The 52-week trading range was $0.95 to $3.23. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.